EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische Studie

An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II

Joseph Muenzer, Barbara K Burton, Paul Harmatz, Deepa S Rajan, Simon A Jones, Johanna M P van den Hout, John J Mitchell, Akhil Bhalla, Natalie J Engmann, Imanol Zubizarreta, Wei Dong, Fabian Model und 4 weitere

New England Journal of Medicine · 2026-01 · 394 (1) · 39-50

DOI: 10.1056/nejmoa2508681 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, 2026-01. Verfasst von Joseph Muenzer und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina School of Medicine, Chapel Hill. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Heparan Sulfate, Iduronate Sulfatase, Mucopolysaccharidosis II. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Denali Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme Replacement TherapyHeparan SulfateIduronate SulfataseMucopolysaccharidosis IIRecombinant Fusion ProteinsAdolescentChildChild, PreschoolHumansMaleBrainInfusions, IntravenousLiverTreatment OutcomeInfant

Substanzen

Heparan SulfateIduronate SulfataseRecombinant Fusion Proteins

Autor:innen und Institutionen

  • University of North Carolina School of Medicine, Chapel Hill.
  • Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago.
  • UCSF Benioff Children's Hospital, Oakland, CA.
  • UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh.
  • Manchester University NHS Foundation Trust, Manchester, United Kingdom.
  • Erasmus University Medical Center, Rotterdam, the Netherlands.

Förderung

  • Denali Therapeutics

Zitieren

APA

Muenzer, J., Burton, B. K., Harmatz, P., Rajan, D. S., Jones, S. A., van den Hout, J. M. P., Mitchell, J. J., Bhalla, A., Engmann, N. J., Zubizarreta, I., Dong, W., Model, F., Watts, R. J., Troyer, M. D., Chin, P. S., & Ho, C. (2026). An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II. New England Journal of Medicine, 394(1), 39-50. https://doi.org/10.1056/nejmoa2508681

Vancouver

Muenzer J, Burton BK, Harmatz P, Rajan DS, Jones SA, van den Hout JMP, et al. An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II. New England Journal of Medicine. 2026;394(1):39-50. doi:10.1056/nejmoa2508681

BibTeX
@article{Muenzer2026,
  author = {Muenzer, Joseph and Burton, Barbara K and Harmatz, Paul and Rajan, Deepa S and Jones, Simon A and van den Hout, Johanna M P and Mitchell, John J and Bhalla, Akhil and Engmann, Natalie J and Zubizarreta, Imanol and Dong, Wei and Model, Fabian and Watts, Ryan J and Troyer, Matthew D and Chin, Peter S and Ho, Carole},
  title = {An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {1},
  pages = {39--50},
  doi = {10.1056/nejmoa2508681}
}
Kostenlos starten →